Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial

le Roux CW, Busetto L, Aronne L, Horn DB, Dimitriadis GK, Falcon B, Garcia-Perez LE, Valderas EG, Gibble TH, Senyucel C, Dunn JP. A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial Diabetes Obes Metab

Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation

Scairati R, Newman C, Dunne FP, Colao A. Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation Diabetes Obes Metab

Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery

Villelabeitia IK, Cohen R, le Roux CW. Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery Heart

Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis

Ateiwi YA, Mahmood R, Wong HJ, Low CE, Yau CE, Lee ARYB, Eng PC, Lee M, Chan MY, Sia CH. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis Diabetes Res Clin Pract

Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity

O'Connor R. Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity Drug Ther Bull

Changes in Eating Behaviour During Treatment With Obesity Medications

Chong MC, Ko TYL, le Roux PL, le Roux CW. Changes in Eating Behaviour During Treatment With Obesity Medications Clin Obes
Appetite & Satiety

Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study

Ozairi EA, Taghadom E, Irshad M, Yousef AA, AlKandari J, Al-Najim W, Alabdulkader S, Miras AD, le Roux CW. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study Diabetes Res Clin Pract
Insulin Resistance & Diabetes

Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?

Brennan DJ, Lynch L. Will GLP-1 Agonists Weaken the Links between Obesity and Cancer? Cancer Discov

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)

le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes Obes Metab

The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice

Alawami F, Novaes O, Gibney J, Phelan N, Behan LA, Owens L. The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice Ir J Med Sci
PCOS

Older posts

Newer posts

← Previous Page1 … Page3 Page4 Page5 … Page30 Next →

Search for:

Recent Posts

10th ASOI Annual Scientific Meeting 2026
9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI